FHL3: A Potential Drug Target for DNA Replication and Repair (G2275)

Target Name: FHL3

NCBI ID: G2275

FHL3

FHL3: A Potential Drug Target for DNA Replication and Repair

FHL3 (Frosinylated DNA-binding protein 3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the FHL1 gene family, which encodes a family of proteins that play a critical role in the regulation of DNA replication and repair. In recent years, researchers have become increasingly interested in studying the function of FHL3 and its potential as a drug target. In this article, we will explore the biology of FHL3, its potential drug target. status, and current research efforts to understand its role in human disease.

Structure and Function

FHL3 is a 22kDa protein that is composed of 115 amino acid residues. It has a characteristic 伪-helices that give it a 尾-hairpin shape. FHL3 is primarily localized to the cytoplasm of cells and is soluble in water. It can interact with DNA in a variety of ways, including through its ability to form a stable complex with DNA-protein complexes.

FHL3 functions as a critical regulator of DNA replication and repair. It plays a key role in the repair of DNA double-strand breaks, which are a common form of genetic damage that can occur during DNA replication. FHL3 is also involved in the regulation of DNA replication fork progresses, which is the process by which a replication fork moves along the double-strand break to replicate the damaged DNA.

In addition to its role in DNA replication and repair, FHL3 is also involved in the regulation of cell growth and differentiation. It has been shown to play a role in the regulation of angiogenesis, the process by which new blood vessels are formed, and in the regulation of stem cell proliferation.

Potential Drug Target

FHL3 is a protein that has potential as a drug target due to its involvement in various cellular processes that are important for human health and disease. Its ability to interact with DNA and its role in regulating DNA replication and repair make it a promising target for small molecules that can modulate these processes.

One potential drug that may target FHL3 is the small molecule inhibitor, SU5415. This compound has been shown to inhibit the activity of FHL3 and to protect against DNA damage in cell culture models of DNA replication repair.SU5415 has also been shown to promote the formation of DNA-protein complexes in cells, which is consistent with FHL3's role in regulating DNA replication.

Another potential drug that may target FHL3 is the anti-inflammatory drug, S100, which has been shown to inhibit the activity of FHL3 in cell culture models of inflammation.S100 also has been shown to promote the production of DNA repair complexes in cells, which is consistent with FHL3's role in regulating DNA replication.

In conclusion, FHL3 is a protein that has potential as a drug target due to its involvement in various cellular processes that are important for human health and disease. Its ability to interact with DNA and its role in regulating DNA replication and repair make it a promising target for small molecules that can modulate these processes. Further research is needed to understand the full scope of FHL3's potential as a drug target and to develop effective therapies for the treatment of diseases that are caused by FHL3-related dysfunction.

Protein Name: Four And A Half LIM Domains 3

Functions: Recruited by SOX15 to FOXK1 promoters where it acts as a transcriptional coactivator of FOXK1

The "FHL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FHL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets